Metraipolis › archive › dc_64f80225532c
Real-World Treatment Outcomes After Nivolumab Progression in BRAF-Negative Metastatic Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group — Europe PMC PMID:42452684
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42452684
- DOI
- 10.3390/jcm15135224
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-18T11:27:40.771Z
- SHA-256 of the archived text
b94da71f60987b56b68f264715d79c0dc76cb348c5a401bebe31ff22a5be6da0- Stable URL of this page
https://metraipolis.com/documento/dc_64f80225532c
How to cite
Real-World Treatment Outcomes After Nivolumab Progression in BRAF-Negative Metastatic Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group — Europe PMC PMID:42452684 — Europe PMC (en), https://europepmc.org/article/MED/42452684 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_64f80225532c (Metraipolis archive dc_64f80225532c, sha256 b94da71f60987b56b68f264715d79c0dc76cb348c5a401bebe31ff22a5be6da0)
BibTeX
@misc{dc64f80225532c,
title = {Real-World Treatment Outcomes After Nivolumab Progression in BRAF-Negative Metastatic Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group — Europe PMC PMID:42452684},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42452684},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_64f80225532c; sha256 b94da71f60987b56b68f264715d79c0dc76cb348c5a401bebe31ff22a5be6da0},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42452684. Agents can read the archived copy with the MCP tool read_document.